尼达尼布治疗肺纤维化对肺功能的影响及不良反应分析

Analysis of the Effects and Adverse Reactions of Nintedanib Treatment on Pulmonary Function in Patients with Pulmonary Fibrosis

摘要: 目的：分析尼达尼布治疗肺纤维化对肺功能的影响。方法：本研究的目标人群为2023年11月1日至2024年7月15日期间就诊，经胸部影像学检查、肺功能检查或组织病理学检查确诊符合肺纤维化相关性疾病诊断标准的600例患者。按1:1比例随机分为观察组(n = 300)和对照组(n = 300)。两组均接受平喘、镇咳、吸氧等基础治疗，观察组额外加用尼达尼布，对照组加用安慰剂。观察患者治疗后肺功能恢复情况及治疗依从性。结果：观察组患者的肺功能高于对照组，差异有统计学意义(P < 0.05)；观察组患者的依从性高于对照组，差异有统计学意义(P < 0.05)。结论：肺纤维化实施尼达尼布的临床治疗，可有效延缓患者的肺功能下降进展，且具有良好的耐受性，利于肺功能指标的稳定，具有较强的推广价值。

Abstract: Objective: To analyze the effects of nintedanib treatment on pulmonary function in patients with pulmonary fibrosis. Methods: The target population of this study consisted of 600 patients diagnosed with pulmonary fibrosis-related diseases based on chest imaging, pulmonary function tests, or histopathological examination, who visited the clinic between November 1, 2023, and July 15, 2024. They were randomly divided into an observation group (n = 300) and a control group (n = 300) in a 1:1 ratio. Both groups received basic treatment, including bronchodilators, antitussives, and oxygen therapy. The observation group received nintedanib in addition to basic treatment, while the control group received a placebo. The recovery of pulmonary function and treatment compliance were observed in both groups. Results: The pulmonary function of patients in the observation group was significantly better than that of the control group, with a statistically significant difference (P < 0.05); the compliance of patients in the observation group was also significantly higher than that of the control group, with a statistically significant difference (P < 0.05). Conclusion: Clinical treatment with nintedanib for pulmonary fibrosis can effectively slow the progression of pulmonary function decline in patients, and it has good tolerability, contributing to the stability of pulmonary function indicators, and has strong potential for wider application.